Woo-Hyuk Song

Dr. Woo-Hyuk Song

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SKSunwon Kim
Sunwon Kim
JLJong-Seok Lee
Jong-Seok Lee
YKYong-Hyun Kim
Yong-Hyun Kim
JKJin-Seok Kim
Jin-Seok Kim
SLSang Yup Lim
Sang Yup Lim
WSWoo-Hyuk Song
Woo-Hyuk Song
Balloon-injured coronary segments are known to harbor abnormal vasomotion. We evaluated whether de novo coronary lesions treated using drug-coated balloon (DCB) are prone to vasospasm and how they respond to ergonovine and nitrate. Among 132 DCB angioplasty recipients followed, 89 patients underwent ergonovine provocation test at 6–9 months follow-up. Within-subject ergonovine- and nitrate-induced diameter changes were compared among three different sites: DCB-treated vs. angiographically normal vs. segment showing prominent vasoreactivity (spastic). No patient experienced clinically refractory vasospastic angina or symptom-driven revascularization during follow-up. Ergonovine induced vasospasm in seven patients; all were multifocal spasm either involving (n = 2) or rather sparing DCB-treated segments (n = 5). None showed focal spasm that exclusively involved DCB-treated lesions. Among 27 patients with vasospastic features, DCB-treated segments showed less vasoconstriction than spastic counterparts (p < 0.001). A total of 110 DCB-treated lesions were analyzed to assess vasomotor function. Vasomotor function, defined as a combined constrictor and dilator response, was comparable between DCB-treated and angiographically normal segments (p = 0.173), while significant differences were observed against spastic counterparts (p < 0.001). In our study, DCB-treated lesions were not particularly vulnerable to vasospasm and were found to have vasomotor function similar to angiographically normal segments, supporting safety of DCB-only strategy in treating de novo native coronary lesions.

Verified
Journal Article
Open access
PDF file
SKSunwon Kim
Sunwon Kim
JLJong-Seok Lee
Jong-Seok Lee
JLjungkuk lee
jungkuk lee
YKYong-Hyun Kim
Yong-Hyun Kim
JKJin-Seok Kim
Jin-Seok Kim
WSWoo-Hyuk Song
Woo-Hyuk Song
Drug-eluting stent (DES) recipients require 6–12 months of dual antiplatelet treatment (DAPT) and long-term aspirin mono-antiplatelet treatment (MAPT). Given the diversity of contemporary antiplatelet agents, antiplatelet treatment (APT) selection is becoming more complicated. We evaluated 15-year APT trends based on nationwide prescription data of 79,654 patients who underwent percutaneous coronary intervention (PCI) using DESs from 2002 to 2018 in Korea. DAPT (80.7%) was the most preferred initial APT post-PCI. Many DES recipients received prolonged DAPT (post-PCI 3 years: 41.0%; 10 years: 27.7%). There was a noticeable delay in DAPT-to-MAPT conversion from the mid to late 2000s (after the late-stent thrombosis concerns of first-generation DESs raised); the conversion after that was similar during the 2010s, occurring most robustly at 12–18 months post-PCI. Clopidogrel had long and increasingly been used for MAPT, surpassing aspirin. The recent increase in newer P2Y12 inhibitor prescriptions was noted. The patients treated with newer P2Y12 inhibitors were more likely younger men and presented with acute myocardial infarction. Real-world APT is evolving, and guideline–practice gaps exist. Further studies exploring the impact of diverse APT strategies on patient outcomes are expected to provide insights into optimal APT that can sophisticatedly balance the ischemic and bleeding risks.

6 December 2019 in Hypertension Research
Verified
Journal Article
Closed access
PDF file
SKSunwon Kim
Sunwon Kim
JLJong-Seok Lee
Jong-Seok Lee
WKWoohyeun Kim
Woohyeun Kim
YKYong-Hyun Kim
Yong-Hyun Kim
JKJin-Seok Kim
Jin-Seok Kim
WSWoo-Hyuk Song
Woo-Hyuk Song